Intranasal pharmaceutical dosage forms comprising naloxone
US11020343B2 · kind B2 · utility
4Cited by
8References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2019 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | Aug 23, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HC dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.